Furthermore, it has been found that WithaD, a chemotherapeutic agent, effectively prevents macrophage M2-polarization by decreasing ERK/STAT3 pathway activation, suppressing breast cancer progression and tumor angiogenesis by eliminating lactate-induced M2 macrophage polarization [87]. This evidence concerns the gene STAT3 and breast cancer.